Mizuho on Maze Therapeutics (MAZE): top-line data from Ph2 study shows 'best-in-class' potential
Tweet Send to a Friend
Mizuho analyst Salim Syed reiterated an Outperform rating and $97.00 price target on Maze Therapeutics (NASDAQ: MAZE)The analyst commented, "This ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
